USD 1.01 billion
Report ID:
SQMIG35J2098 |
Region:
Global |
Published Date: February, 2024
Pages:
157
|Tables:
90
|Figures:
76
Global Breast Cancer Liquid Biopsy Market size was valued at USD 1.01 billion in 2022 and is poised to grow from USD 1.24 billion in 2023 to USD 6.37 billion by 2031, growing at a CAGR of 22.7% during the forecast period (2024-2031).
The global breast cancer liquid biopsy market has experienced significant growth and innovation in recent years, driven by increasing awareness and adoption of non-invasive diagnostic techniques. The technology's ability to detect tumor-specific genetic mutations, circulating tumor cells, and cell-free DNA provides crucial information for early detection, treatment selection, and monitoring of treatment response. Additionally, ongoing research and development efforts are likely to lead to enhanced sensitivity and specificity of liquid biopsy tests, driving further market expansion.
As the medical community embraces this innovative approach, the global breast cancer liquid biopsy market is expected to experience substantial growth in the coming years. The technology's ability to detect tumor-specific biomarkers, circulating tumor cells (CTCs), and cell-free DNA in blood samples has revolutionized cancer diagnostics and treatment monitoring. Moreover, the market has been fueled by ongoing research and development efforts, collaborations between biotech companies and healthcare institutions, and a rising demand for personalized and targeted therapies for breast cancer patients.
US Breast Cancer Liquid Biopsy Market is poised to grow at a sustainable CAGR for the next forecast year.
Global Market Size
USD 1.01 billion
Largest Segment
Hospitals
Fastest Growth
Hospitals
Growth Rate
22.7% CAGR
To get more reports on the above market click here to Buy The Report
Global Breast Cancer Liquid Biopsy Market is segmented by circulating biomarkers, application, end users and region. Based on circulating biomarkers, the market is segmented into circulating tumor cells (CTCS), circulating cell-free DNA (CFDNA), extracellular vesicles (EVS) and other circulating biomarkers. Based on application, the market is segmented into early detection/screening, diagnosis, treatment selection and monitoring. Based on end users, the market is segmented into hospitals, clinics and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Breast Cancer Liquid Biopsy Market Analysis By Technology
The largest sector in the breast cancer liquid biopsy market is likely to be the cfDNA-based technology, which involves the analysis of fragmented DNA released by cancer cells into the bloodstream.
Meanwhile, the fastest-growing sector in the breast cancer liquid biopsy market is expected to be extracellular vesicle-based technology. Extracellular vesicles, such as exosomes, play a crucial role in intercellular communication, and their cargo often includes genetic material and proteins originating from cancer cells.
Breast Cancer Liquid Biopsy Market Analysis By Biomarker
Circulating tumor DNA (ctDNA) has emerged as the largest and most dominant sector within the global breast cancer liquid biopsy market. ctDNA analysis allows for the detection of specific genetic mutations or alterations in the tumor, providing valuable insights into disease progression and treatment response.
Simultaneously, the fastest-growing sector in the breast cancer liquid biopsy market pertains to extracellular vesicles (EVs). These vesicles hold great promise as potential biomarkers due to their ability to reflect the heterogeneous nature of tumors and their role in intercellular communication.
To get detailed analysis on other segments, Request For Free Sample Report
North America led the way with a strong presence of key market players, advanced healthcare infrastructure, and growing adoption of liquid biopsy technologies. Europe demonstrated significant growth due to increased awareness, supportive government initiatives, and rising research and development activities. The Asia-Pacific region exhibited substantial potential, driven by a large patient pool, expanding healthcare expenditure, and increasing focus on personalized medicine. Latin America and the Middle East/Africa regions also experienced a gradual uptick in liquid biopsy adoption, with improving healthcare facilities and a greater emphasis on cancer diagnostics.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Breast Cancer Liquid Biopsy Market Drivers
Increasing Need to Address Breast Cancer
Breast Cancer Liquid Biopsy Market Restraints
Lack of Investment for Healthcare Infrastructure
Request Free Customization of this report to help us to meet your business objectives.
The global breast cancer liquid biopsy market was witnessing intense competition among key players. Companies in this space were continuously focusing on technological advancements, strategic collaborations, and product innovations to gain a competitive edge. The market was characterized by a diverse range of liquid biopsy solutions aimed at detecting breast cancer-related biomarkers in a non-invasive manner. Additionally, the growing emphasis on early cancer detection and personalized medicine was fueling the demand for liquid biopsy products, driving further competition and market growth.
Breast Cancer Liquid Biopsy Market Top Player’s Company Profiles
Breast Cancer Liquid Biopsy Market Recent Developments
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Product types team that Collects, Collates, Co-relates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
According to our analysis, the global breast cancer liquid biopsy market holds promising future prospects, poised for substantial growth and advancements. The growing interest in precision oncology, which aims to deliver targeted therapies based on a patient's unique genetic profile, has fueled the demand for liquid biopsy tests that provide essential genomic information for treatment decision-making. Liquid biopsies enable the identification of specific genetic mutations and alterations in breast cancer patients. This information allows healthcare professionals to tailor treatment strategies and select targeted therapies for individual patients, driving the demand for liquid biopsy tests.
Report Metric | Details |
---|---|
Market size value in 2022 | USD 1.01 billion |
Market size value in 2031 | USD 6.37 billion |
Growth Rate | 22.7% |
Base year | 2023 |
Forecast period | 2024-2031 |
Forecast Unit (Value) | USD Billion |
Segments covered |
|
Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
Companies covered |
|
Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
For the Breast Cancer Liquid Biopsy Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Breast Cancer Liquid Biopsy Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Breast Cancer Liquid Biopsy Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Breast Cancer Liquid Biopsy Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Report ID: SQMIG35J2098
sales@skyquestt.com
USA +1 351-333-4748